Lilly Joins the Push for Non-Opioid Painkillers In PharmaLilly joins the push for non-opioid painkillers 03-Jun-2019 By Maggie Lynch Eli Lilly acquires exclusive worldwide rights for non-opioid treatment for chronic pain from Centrexion through a licensing agreement. HTTPS://WWW.IN-PHARMATECHNOLOGIST.COM/ARTICLE/2019/06/03/ELI-LILLY-LICENSES-NON-OPIOID-TREATMENT-FOR-47.5M PPLadmin2020-12-10T19:32:22+00:00 Share This Story, Choose Your Platform! FacebookTwitterRedditLinkedInTumblrPinterestVkEmail About the Author: PPLadmin Related Posts https://investorplace.com/2021/01/7-equity-crowdfunding-offerings-to-buy-this-week-current/ https://investorplace.com/2021/01/7-equity-crowdfunding-offerings-to-buy-this-week-current/ January 28th, 2021 Phoenix PharmaLabs Announces new Offering with Netcapital Gallery Phoenix PharmaLabs Announces new Offering with Netcapital January 19th, 2021 Phoenix PharmaLabs Strengthens its Position as a Developer of Next Generation Pain Pharmaceuticals with Acquisition of a Portfolio of NOP/Mu Agonist Compounds Gallery Phoenix PharmaLabs Strengthens its Position as a Developer of Next Generation Pain Pharmaceuticals with Acquisition of a Portfolio of NOP/Mu Agonist Compounds January 8th, 2021
